Other: MSCs ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04749667 (ClinicalTrials.gov) | August 9, 2021 | 20/1/2021 | Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis | Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis | Multiple Sclerosis;Progressive Multiple Sclerosis | Other: MSCs;Drug: Saline | Haukeland University Hospital | University of Bergen;University Hospital Ulm;University Hospital, Akershus;St. Olavs Hospital;University Hospital of North Norway | Recruiting | 18 Years | 55 Years | All | 18 | Phase 1/Phase 2 | Norway |